Literature DB >> 15842592

Adenomas in young patients: what is the optimal evaluation?

Elena M Stoffel, Sapna Syngal.   

Abstract

Colorectal adenomas are a known risk factor for colorectal cancer. The prevalence of colorectal adenomas among individuals under age 40 and the clinical implications of finding a single adenoma in a young individual have not been defined. Until the most recent revision of the Bethesda Guidelines, having one or more adenomas diagnosed at age <40 was an indication for evaluation for hereditary nonpolyposis colorectal cancer (HNPCC). In an effort to explore the association of young-onset adenomas with HNPCC, Velayos et al. tested adenomas from 34 subjects aged 18-39 for pathologic features of HNPCC. Finding that none of the young-onset adenomas demonstrated features of microsatellite instability (MSI) or loss of mismatch repair protein expression by immunohistochemistry (IHC), the authors conclude that the yield of such testing is low, and support the decision to exclude young-onset adenomas from the Revised Bethesda Guidelines for HNPCC. However, this study also revealed that MSI and IHC failed to detect abnormalities in half of the adenomas from control subjects with identified MLH1 and MSH2 mutations. These findings highlight the limitations of current molecular techniques for examining adenomas as an initial screen for HNPCC and the need for further studies evaluating the optimal genetic and clinical evaluation of patients with young-onset adenomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842592     DOI: 10.1111/j.1572-0241.2005.41967.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Advanced colorectal adenomas in patients under 45 years of age are mostly sporadic.

Authors:  Vladimir M Kushnir; Ilke Nalbantoglu; Rao Watson; Jonathan Goodwin; Elyas Safar; Reena V Chokshi; Riad R Azar; Nicholas O Davidson
Journal:  Dig Dis Sci       Date:  2014-06-13       Impact factor: 3.199

2.  A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.

Authors:  Lyn Schofield; Fabienne Grieu; Jack Goldblatt; Benhur Amanuel; Barry Iacopetta
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

Review 3.  Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review.

Authors:  Scott M Weissman; Cecelia Bellcross; Christina Chimera Bittner; Mary E Freivogel; Joy Larsen Haidle; Pardeep Kaurah; Anna Leininger; Selvi Palaniappan; Kelle Steenblock; Thuy M Vu; Molly S Daniels
Journal:  J Genet Couns       Date:  2010-10-08       Impact factor: 2.537

4.  Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Sally-Ann Pearson; Mark Clendenning; Mark A Jenkins; Aung Ko Win; Rhiannon J Walters; Kevin J Spring; Belinda Nagler; Erika Pavluk; Sven T Arnold; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry Phillips; John L Hopper; Jeremy R Jass; John A Baron; Dennis J Ahnen; Stephen N Thibodeau; Noralane Lindor; Susan Parry; Neal I Walker; Christophe Rosty; Joanne P Young
Journal:  Mod Pathol       Date:  2012-02-10       Impact factor: 7.842

5.  Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer.

Authors:  Alexandros D Polydorides; Bhramar Mukherjee; Stephen B Gruber; Barbara J McKenna; Henry D Appelman; Joel K Greenson
Journal:  Am J Surg Pathol       Date:  2008-11       Impact factor: 6.394

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.